EPREX. 3 UI 0.3 ml. 6 syringes JANSSEN CILAG
EPREX. 3 UI 0.3 ml. 6 syringes JANSSEN - CILAG
EPREX epoetin alpha protein that stimulates the bone marrow to produce more red blood cells. It represents a copy of the human protein erythropoietin and works in the same way.
* Anemia associated with CKD in adults and children on hemodialysis , peritoneal dialysis ;
* Anemia in cancer patients with non-myeloid malignancies (with or without chemotherapy) ;
* Anemia in HIV patients , including . treated with zidovudine, whose endogenous erythropoietin levels are less than 500 mU / ml.
* Epoetin alpha is also used to shorten the time of collection of autologous blood in patients with hematocrit 33-38 % , scheduled for major surgery , requiring a larger volume of blood.
Dosage and method of administration
In CRF epoetin alpha can be strictly applied only intravenously . The dosage of the product is strictly individual . During the so-called " phase correction " is applied , higher doses to achieve a normal hemoglobin values , then the dosage is decreased during the " maintenance phase " .
At the beginning of treatment - " flu-like " symptoms ( dizziness, drowsiness , fever , headache, joint and muscle pain , malaise) . The most common ADRs are dose-dependent increase in blood pressure or aggravation of existing hypertension. This is most commonly seen in patients with CRF. In individual patients , incl. with normal blood pressure may develop hypertensive crisis with malignant hypertension entsefalopatichni symptoms ( headache, confusion ) and generalized tonic- clonic seizures. In rare cases during treatment with epoetin alpha develop thrombocytosis and trombovaskularni incidents - AMI , cerebrovascular disorders ( stroke) , deep vein thrombosis , without a causal link between the medicine and the symptoms . The occurrence of shunt thrombosis in patients on hemodialysis and development eritroblastopepiya associated with subcutaneous administration of epoetin alpha in patients with CRF. Therefore, when CRF is administered epoetin alpha strictly only intravenously . Also describe skin rashes , eczema, urticaria, pruritus , angioedema . For subcutaneous injection, local reactions were observed at the injection site of epoetin alpha. In patients with CKD are described overload , hyperphosphatemia , hyperuricemia , and hiperkreatipemiya hiperuremiya .